- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Captor Therapeutics SA (CTXP)
Captor Therapeutics SA stock price live, this page displays WA CTXP stock exchange data. View the CTXP premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Captor Therapeutics SA real time stock price chart below.
What Is the Captor Therapeutics SA Stock Price Today?
The Captor Therapeutics SA stock price today is 79.00.
What Is the Stock Symbol for Captor Therapeutics SA?
The stock symbol for Captor Therapeutics SA is "CTXP."
What Stock Exchange Does Captor Therapeutics SA Trade On?
Captor Therapeutics SA is listed and trades on the Warsaw stock exchange.
Is Captor Therapeutics SA a Good Stock to Buy?
Determining whether Captor Therapeutics SA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CTXP quote. (ISIN: PLCPTRT00014)
What Is the Captor Therapeutics SA Stock Price Today?
The Captor Therapeutics SA stock price today is 79.00.
What Is the Stock Symbol for Captor Therapeutics SA?
The stock symbol for Captor Therapeutics SA is "CTXP."
What Stock Exchange Does Captor Therapeutics SA Trade On?
Captor Therapeutics SA is listed and trades on the Warsaw stock exchange.
Is Captor Therapeutics SA a Good Stock to Buy?
Determining whether Captor Therapeutics SA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CTXP quote. (ISIN: PLCPTRT00014)
79.00
+2.50(+3.27%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
75.40
79.00
52 wk Range
31.50
89.20
CTXP is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
75.4079.00
52 wk Range
31.5089.20
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
CTXP Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
86.83
Upside
+9.92%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Stock generally trades with low price volatility
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy
Analyst Ratings
3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 86.83
(+9.92% Upside)
Earnings
Latest Release
Jun 02, 2026
EPS / Forecast
-- / --
Revenue / Forecast
-- / 3M
Compare CTXP to Peers and Sector
Metrics to compare | CTXP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCTXPPeersSector | |
|---|---|---|---|---|
P/E Ratio | −11.8x | −7.4x | −0.4x | |
PEG Ratio | −2.18 | 0.08 | 0.00 | |
Price/Book | 41.6x | 3.1x | 2.6x | |
Price / LTM Sales | 210.7x | 3.7x | 3.0x | |
Upside (Analyst Target) | 5.7% | 135.1% | 58.1% | |
Fair Value Upside | Unlock | 4.0% | 8.2% | Unlock |
Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, develops therapeutic molecules for treating oncological and autoimmune diseases in Poland. The company offers targeted protein degradation technology that utilizes the Optigrade drug discovery platform to overcome the limitations of inhibitors and antibody drugs by destroying disease-causing proteins that are resistant to available therapeutics. It develops viadrudomide, which is in a Phase 1 clinical trial for hepatocellular carcinoma (HCC), lung cancer, and rare cancers; vratitoclax, a bifunctional MCL-1 protein degrader that is in the CTA-enabling stage for liquid and solid tumors; CT-02B, a NEK7 degrader that is in preclinical trials for neuroinflammation indications in Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS); CT-02S, a NEK7 degrader that is in preclinical trials for systemic autoimmunity indications in inflammatory bowel diseases (IBD), gout, and dermatological diseases; and CT-05, a PKCtheta degrader that is in preclinical trials for autoimmunity, transplantation, and metabolism indications. In addition, the company’s candidates in the discovery phase include an undisclosed project for oncology, autoimmunity, CNS, and rare indications; and novel E3 ligases for oncology and autoimmunity indications. Captor Therapeutics Spolka Akcyjna was incorporated in 2015 and is headquartered in Wroclaw, Poland.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Captor Therapeutics (CTXP) Stock Price Today?
The Captor Therapeutics stock price today is 79.00 PLN.
What Stock Exchange Does Captor Therapeutics Trade On?
Captor Therapeutics is listed and trades on the Warsaw Stock Exchange.
What Is the Stock Symbol for Captor Therapeutics?
The stock symbol for Captor Therapeutics is "CTXP."
What Is the Captor Therapeutics Market Cap?
As of today, Captor Therapeutics market cap is 501.92M PLN.
What Is Captor Therapeutics's Earnings Per Share (TTM)?
The Captor Therapeutics EPS (TTM) is -7.71.
When Is the Next Captor Therapeutics Earnings Date?
Captor Therapeutics will release its next earnings report on Sep 03, 2026.
From a Technical Analysis Perspective, Is CTXP a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Captor Therapeutics Stock Split?
Captor Therapeutics has split 0 times.
How Many Employees Does Captor Therapeutics Have?
Captor Therapeutics has 82 employees.
What is the current trading status of Captor Therapeutics (CTXP)?
As of Jun 22, 2026, Captor Therapeutics (CTXP) is trading at a price of 79.00 PLN, with a previous close of 76.50 PLN. The stock has fluctuated within a day range of 75.40 PLN to 79.00 PLN, while its 52-week range spans from 31.50 PLN to 89.20 PLN.
What Is Captor Therapeutics (CTXP) Price Target According to Analysts?
The average 12-month price target for Captor Therapeutics is 86.83 PLN, with a high estimate of 110 PLN and a low estimate of 67 PLN. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +9.92% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.